In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
|Articles|August 1, 2011
- Applied Clinical Trials-08-01-2011
- Volume 20
- Issue 8
Applied Clinical Trials Digital Edition - August 2011
CRO/SPONSOR : Clinical Contracting Efficiency Can Save Millions REGULATORY : Common Technical Document Development - A Partnership Approach Also in this issue : FDA Looks to Collaborate Overseas, EU Reviews, Clinical Trial Rules, Meaningful Web, Greater Trial Insight
Advertisement
Articles in this issue
about 15 years ago
Applied Clinical Trials Digital Edition - August 2011, Supplementabout 15 years ago
Change the CT Rules, but to What Precisely?about 15 years ago
EFGCP Advocates Change to Consent Processabout 15 years ago
Digital Data, the Semantic Web, and Researchabout 15 years ago
Business and News Update August 2011about 15 years ago
An Idea Whose Time Cameabout 15 years ago
FDA Seeks New Approach to Global Challengesabout 15 years ago
In Pursuit of Enlightenmentabout 15 years ago
Clinical Contracting Efficiencyabout 15 years ago
Latin America Research StatsAdvertisement
Related to this article
Cell and gene therapy access expands into community care settings only when operational coordination, site readiness, and supply chain standardization become first-order priorities equivalent to manufacturing capacity, requiring standardized processes, digital integration, and distributed logistics networks.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
In today's ACT Brief, we examine understanding the patient journey from end to end, whether decentralization reduces site burden or just shifts it, and why nine European drugmakers are sounding urgent alarms.
Decentralized trial models have demonstrated real gains in enrollment performance and patient access, but operational switching costs, fragmented technology stacks, and unresolved gaps in the patient-site relationship raise a question the industry has been slow to confront directly.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey from beginning to end—and building that understanding into both study design and data collection tools—remains one of the industry's most important unfinished tasks.
In today's ACT Brief, we examine technology's real role in patient-site collaboration, why AI pilot failures stem from organization not innovation, and Novo's weight-loss drug results in competitive comparison.
Most AI pilots in drug development fail not from poor technology but from lack of strategic prioritization, organizational readiness, integrated data infrastructure, and disciplined governance, making success dependent on business discipline rather than technical capability.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development
2
Clinical Site Readiness for Cell and Gene Therapies: Operational and Supply Chain Challenges as they Scale and as they Expand into the Community Care Setting
3
Is Decentralization Actually Reducing Site Burden, or Just Moving It?
4
Beyond Compliance: Vivalink's Cecilia Xi, PhD, on Data Provenance and Sustainable Device Strategy in Clinical Trials
5